Pacific Edge Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PFGTF research report →
Companywww.pacificedgedx.com
Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore. It operates in two segments, Commercial and Research. The company offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer.
- CEO
- Peter Meintjes
- IPO
- 2016
- Employees
- 114
- HQ
- Dunedin, NZ
Price Chart
Valuation
- Market Cap
- $197.62M
- P/E
- -6.79
- P/S
- 13.30
- P/B
- 8.72
- EV/EBITDA
- -6.36
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 26.21%
- Op Margin
- -221.76%
- Net Margin
- -205.33%
- ROE
- -130.42%
- ROIC
- -122.76%
Growth & Income
- Revenue
- $21.85M · -16.18%
- Net Income
- $-29,936,000 · -1.36%
- EPS
- $-0.04 · -1.65%
- Op Income
- $-34,103,000
- FCF YoY
- 4.09%
Performance & Tape
- 52W High
- $0.23
- 52W Low
- $0.02
- 50D MA
- $0.10
- 200D MA
- $0.11
- Beta
- 0.74
- Avg Volume
- 83
Get TickerSpark's AI analysis on PFGTF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PFGTF Coverage
We haven't published any research on PFGTF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PFGTF Report →